- GR-MD-02 was safe and well tolerated in patients
- Galectin Therapeutics to host webcast, April 1, 8:30 a.m. EDT to discuss first cohort findings
- Second cohort of Phase 1 trial to begin enrollment in April
These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.
Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?